G1 Therapeutics RALLY

Earnings/News

• Co's lead cancer therapy, trilaciclib, gets FDA's "breakthrough therapy" status, which is meant to speed up review of drugs that treat life-threatening conditions
  
  
• GTHX says it will present new data on three of its drugs, including trilaciclib, at an upcoming conference in September
  
  
• FDA's move is a recognition that clinical data presented so far reflects the potential for trilaciclib to address an urgent unmet medical need - Cowen & Co
  
  

Analyst Actions
JP Morgan Upgrades G1 Therapeutics to Overweight From Neutral, PT Raised to $45 From $38